Be careful of what you wish for: putting the WHI Estrogen/Progestin and HERS II Trials in perspective.
Randolph
John F
JF
Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, University of Michigan Health System, Ann Arbor, USA.
D001943:Breast Neoplasms / Q000453:epidemiology; D002318:Cardiovascular Diseases / Q000517:prevention & control; D002986:Clinical Trials as Topic; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage; D005260:Female; D006801:Humans; D017698:Postmenopause; D045167:Progesterone Congeners / Q000008:administration & dosage; D011446:Prospective Studies; D012307:Risk Factors; D016387:Women's Health
D004966:Estrogens, Conjugated (USP); D045167:Progesterone Congeners